Alkermes earnings were $152.7M for the trailing 12 months ending Mar 31, 2026, with -56.7% growth year over year. The latest ALKS earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$66.5M, down 234.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ALKS reported annual earnings of $241.7M, with -34.2% growth.
ALKS past earnings growth
How has ALKS's earnings growth performed historically?
On ALKS's earnings call on Invalid Date, Alkermes (NASDAQ: ALKS) reported Q1 2026 earnings per share (EPS) of -$0.40, up 385.71% year over year. Total ALKS earnings for the quarter were -$66.48 million. In the same quarter last year, Alkermes's earnings per share (EPS) was $0.14.
As of the last Alkermes earnings report, Alkermes is currently profitable. Alkermes's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $152.72 million, a 56.7% decrease year over year.
What was ALKS's earnings growth in the past year?
As of Alkermes's earnings date in Invalid Date, Alkermes's earnings has grown -56.74% year over year. This is 89.41 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 32.67%. ALKS earnings in the past year totalled $152.72 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.